Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care
Timothy F. Burns, MD, PhD
Gerard A. Silvestri MD, MS
Getting Trial-Ready: Matching Patients to Frontline Studies of KRAS G12C Inhibitors
From Biopsy to Results: Building a Reflex-Ready Testing Workflow
SOHO 2026 Debrief: Translating the Latest CLL Data Into Community Practice Decisions
Jennifer R. Brown, MD, PhD
From Disease Assessment to Advanced Therapy: A Practical Framework for Atopic Dermatitis
Kristine Kucera, PA-C, MPAS, DHSc
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Komal Jhaveri, MD, FACP
Virginia Kaklamani, MD, DSc
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
Saad Z. Usmani, MD, MBA
Natalie S. Callander, MD
Navigating the Evidence: Emerging Frontline Combination Strategies in KRAS G12C NSCLC
Oral SERDs and PROTACs in ER+/HER2− mBC: Testing Smarter, Treating Better
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
Safety Considerations and AE Monitoring for Trial Participation With Combination Regimens
KRAS G12C Biology: Why Is This Mutation Different?
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
Amer Zeidan, MBBS
Ghayas Issa, MD
Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
Kathleen N. Moore, MD
Ritu Salani, MD
Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer
The Frontline Imperative: Integrating Anti-CD38–Based Regimens Into Multiple Myeloma Care in Community Practice
Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer
Treatment Decisions That Matter: A Case-Based Discussion in Advanced Ovarian Cancer
The CELMoD Shift: Translating Protein Degradation Science Into Practice-Changing Myeloma Care
December 11, 2026 New Orleans, Louisiana
Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs
Sara A. Hurvitz, MD, FACP
Tiffany Traina, MD
The Survival Ceiling in ES-SCLC: Why Checkpoint Blockade Alone Is Not Enough
Neal Ready, MD, PhD
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.